Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Crinecerfont · Crenessity, NBI-74788

Small molecule · Antagonist of CRF type 1 receptor (CRHR1) · developed by Neurocrine

Approved FDA, Dec 2024

NBIX Developer

1 Registered trials

What is Crinecerfont?

Crinecerfont is a selective corticotropin-releasing factor type 1 receptor antagonist that blocks CRF binding to CRF1 receptors in the pituitary, inhibiting ACTH secretion and reducing adrenal androgen production.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Crenessity, NBI-74788, SSR-125543
Drug type: Small molecule
Targets: CRF type 1 receptor (CRHR1)
Mechanism: Antagonist of CRF type 1 receptor (CRHR1)
Pathways: ACTH secretion, adrenal androgen production
Therapy area: Endocrine
Developer: Neurocrine (NBIX)
FDA status: Approved as Crenessity (December 13, 2024), NDA218808 · FDA label
UNII: MFT24BX55I

✅ FDA-approved uses

Classic congenital adrenal hyperplasia

From the indications section of the FDA label (version of Dec 24, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04806451	Phase 3	Congenital Adrenal Hyperplasia	Active not recruiting	NBIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Congenital Adrenal Hyperplasia

More from Neurocrine

Valbenazine FDA approved Chronocort Phase 3 DITEST Phase 1 Luvadaxistat Phase 2 NBI-1065845 Phase 3 NBI-1065890 Phase 2 NBI-1070770 Phase 2 NBI-1117567 Phase 2 NBI-1117568 Phase 3 NBI-1117570 Phase 2 NBI-827104 Phase 2 NBI-921352 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the NBIX page.

Follow NBIX, the company behind Crinecerfont

See NBIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NBIX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z